Schubert & Co’s Neurocrine Biosciences NBIX Stock Holding History

Schubert & Co’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8	Closed	-$810	–	976
2023 Q1	$810	Hold	8	–	–	﹤0.01%	1284
2022 Q4	$956	Buy	8 +1	+14%	+$117	﹤0.01%	1193
2022 Q3	$1K	Buy	7 +2	+40%	+$203	﹤0.01%	1178
2022 Q2	$0	Sell	5 -1	-17%	-$92	﹤0.01%	1540
2022 Q1	$1K	Buy	6 +2	+50%	+$169	﹤0.01%	814
2021 Q4	$0	Buy	+4	New	+$368	﹤0.01%	1186

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Schubert & Co's NBIX Position: Q2 2023 in Review

Schubert & Co sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 8 shares — an estimated $810 sold.

Schubert & Co first reported a position in NBIX in Q4 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

Schubert & Co reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 8 Neurocrine Biosciences shares in Q2 2023, an estimated $810.
Schubert & Co first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 6 quarters.
Schubert & Co's Neurocrine Biosciences position peaked at $1K in Q3 2022.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.